8 Best Gene-Editing Stocks to Buy

5. Sanofi (NASDAQ:SNY)

Number of Hedge Fund Holders: 33 

Sanofi (NASDAQ:SNY) is a global healthcare company that develops and markets a wide range of pharmaceutical products, vaccines, and consumer healthcare items. Its portfolio includes treatments for diseases like cancer, multiple sclerosis, diabetes, and rare diseases, as well as vaccines for bacterial and viral infections. The company generates revenue through sales to healthcare providers, pharmacies, and consumers. The company is also expanding its gene-editing and gene therapy capabilities by partnering with innovative biotech firms, positioning itself as a key player in the gene-editing market.

Sanofi (NASDAQ:SNY) strengthened its gene-editing capabilities through an expanded partnership with Scribe Therapeutics in January 2025, focusing on in vivo genetic medicines for sickle cell disease (SCD) and other genomic disorders. The collaboration includes the company’s exclusive use of Scribe’s CRISPR X-Editing (XE) technology for in vivo therapies. The initial focus is on developing a streamlined SCD treatment using CRISPR XE technology combined with the company’s non-viral delivery systems, which could improve patient access and reduce complications compared to ex vivo treatments. Success in SCD could lead to broader applications for other genomic diseases, making Sanofi one of the best gene editing stocks in the field.

Sanofi (NASDAQ:SNY) reported €41.1 billion in total revenues for FY 2024, a rise of 11.3% at constant exchange rates (CER). In its first full year, Dupixent made almost €13 billion, while Beyfortus, a new RSV vaccine for infants, made €1.7 billion and became a blockbuster. Despite a 1.8% drop in reported terms, SNY’s EPS increased 4.1% at CER to €7.12, beyond expectations. The company also suggested paying out €3.92 per share in dividends in 2024, which it has grown for 30 consecutive years.